Document Type
Article
Publication Date
4-21-2021
Abstract
Proteasomal dysfunction is known to be associated with amyotrophic lateral sclerosis and frontotemporal degeneration (ALS/FTD). Our previous reports have shown that a mutant form of ubiquilin-2 (UBQLN2) linked to ALS/FTD leads to neurodegeneration accompanied by accumulations of the proteasome subunit Rpt1 in transgenic rats, but the precise pathogenic mechanisms of how this mutation impairs the proteasome remains to be elucidated. Here, we reveal that this UBQLN2 mutation in rats disrupted the proteasome integrity prior to neurodegeneration, that it dissociated the 26S proteasome in vitro, and that its depletion did not affect 26S proteasome assembly. During both disease progression and in an age-dependent manner, we found that proteasome subunits were translocated to the nucleus, including both of the 20S core particles (PSMA1 and PSMB7) and the 19S regulatory particles (Rpt1 and Rpn1), suggesting that defective proteasome function may result from the proteasome-subunit mislocalization. Taken together, the present data demonstrate that impaired proteasome assembly is an early event in the pathogenesis of UBQLN2-associated neurodegeneration in mutant UBQLN2 rats.
Recommended Citation
Zhang, Wenjuan; Huang, Bo; Gao, Limo; and Huang, Cao, "Impaired 26S Proteasome Assembly Precedes Neuronal Loss in Mutant UBQLN2 Rats." (2021). Department of Pathology, Anatomy, and Cell Biology Faculty Papers. Paper 313.
https://jdc.jefferson.edu/pacbfp/313
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
PubMed ID
33919255
Language
English
Comments
This article is the author's final published version in International Journal of Molecular Sciences, Volume 22, Issue 9, 1 May 2021, Article number 4319.
The published version is available at https://doi.org/10.3390/ijms22094319.
Copyright © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/)